Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

ABSTRACT:

Context

Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of action, DPP-4 inhibitors improve glucose tolerance after meals by increasing insulin and reducing glucagon levels in the plasma. However, DPP-4 inhibitors also reduce fasting blood glucose, an unexpected effect because circulating levels of active GIP and GLP-1 are low in the postabsorptive state.

Objective

The objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function.

Design

We conducted a randomized, double-blind, placebo-controlled t

SUBMITTER: D'Alessio DA 

PROVIDER: S-EPMC2630874 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature